Business context and reporting period
Koninklijke Philips N.V. filed this audited Form 20-F on February 20, 2024, covering the fiscal year ended December 31, 2023. Although the request metadata refers to 2023 Q4, the supplied filing reports full-year results; it does not provide a clear standalone Q4 financial summary. The consolidated financial statements are prepared under IFRS as issued by the IASB. Philips is a health technology company operating through Diagnosis & Treatment, Connected Care and Personal Health.
Financial performance
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Sales | EUR 18.169 billion | EUR 17.827 billion |
| Nominal sales growth | 1.9% | 3.9% |
| Comparable sales growth | 6.0% | (2.8)% |
| Gross margin | EUR 7.448 billion; 41.0% of sales | EUR 7.194 billion; 40.4% of sales |
| Income (loss) from operations | EUR (115) million | EUR (1.529) billion |
| Net income (loss) | EUR (463) million | EUR (1.605) billion |
| Adjusted EBITA | EUR 1.921 billion; 10.6% of sales | EUR 1.318 billion; 7.4% of sales |
| Operating cash flow | EUR 2.136 billion | EUR (173) million |
| Free cash flow | EUR 1.582 billion | EUR (961) million |
Sales growth on a comparable basis excludes currency and consolidation effects; Philips reported a 4.1% negative currency effect in 2023. Comparable sales growth by segment was 11.1% for Diagnosis & Treatment, 1.1% for Connected Care and 3.2% for Personal Health. Adjusted EBITA and free cash flow are non-IFRS measures and should be considered alongside their IFRS comparators.
Debt and liquidity
At year-end, gross debt was EUR 7.689 billion, down from EUR 8.201 billion, and net debt was EUR 5.820 billion, down from EUR 7.028 billion. Cash and cash equivalents were EUR 1.869 billion, compared with EUR 1.172 billion; shareholders’ equity was EUR 12.028 billion. Available liquidity, including cash, listed equity investments and a EUR 1 billion committed revolving facility, was EUR 2.883 billion. The facility was undrawn. Long-term debt represented 91.5% of total debt, with a 6.0-year average remaining term. Credit ratings were BBB+ (stable) from Fitch, Baa1 (negative) from Moody’s and BBB+ (negative) from S&P.
Material changes versus prior year
- Comparable sales returned to growth, up 6.0% after a 2.8% decline in 2022; management attributed the improvement largely to better supply availability and execution.
- Adjusted EBITA margin rose to 10.6% from 7.4%, supported by higher sales, pricing and productivity measures, partly offset by inflation.
- The IFRS net loss narrowed from EUR 1.605 billion to EUR 463 million. The comparison is affected by EUR 1.5 billion of goodwill and R&D impairments in 2022; 2023 earnings included a EUR 575 million Respironics litigation provision.
- Operating cash flow and free cash flow improved substantially, with management citing higher cash earnings and lower working capital.
- Comparable order intake fell 5%, following a 3% decline in 2022, despite a strong absolute order book.
- Workforce fell by 7,577 FTEs to 69,656. Approximately 8,000 roles had been reduced toward a target of 10,000 by 2025.
Outlook, risks and unusual items
- Management expects further performance improvement in 2024 through actions on patient safety and quality, supply-chain reliability and operating-model simplification. The filing text does not provide a clear quantified 2024 financial forecast.
- Philips proposed a EUR 0.85-per-share dividend, payable entirely in shares, subject to shareholder approval. The 2023 dividend was also EUR 0.85 per share and paid in shares.
- Respironics recall and consent decree: More than 99% of actionable sleep-therapy device registrations had been remediated by year-end; ventilator remediation remained ongoing. On January 29, 2024, Philips announced agreement on proposed consent-decree terms with the DOJ and FDA. The decree was still being finalized for court approval at the filing date. Philips said US sales of new CPAP, BiPAP and other respiratory-care devices would not resume until applicable decree requirements are met. The company recorded EUR 363 million of charges related to the proposed decree, including remediation, inventory write-downs and onerous contracts.
- Litigation and investigations: A US economic-loss class-action settlement received preliminary court approval; final approval was scheduled for April 11, 2024. Philips recorded a EUR 575 million provision for the settlement. Personal-injury and medical-monitoring claims, a DOJ investigation, and other recall-related proceedings remained ongoing; the filing states that possible obligations in several matters cannot be reliably estimated. Insurance recoveries were not reliably quantifiable.
- Other notable charges included EUR 224 million of Respironics running remediation costs, EUR 175 million for quality remediation actions and EUR 285 million of restructuring charges. The 2023 net loss also reflected EUR 314 million of net financial expense.
- Key risks include product safety and quality, recall remediation and regulatory compliance, geopolitical and macroeconomic uncertainty, supply-chain disruption, cybersecurity, execution of the simplified operating model, litigation, currency and financing risks, and inflation.
- The auditor issued an unqualified opinion on the IFRS financial statements and on internal control over financial reporting. Management and the auditor concluded that internal control was effective as of December 31, 2023.
Important facts for investors to verify
- Progress, cost and timing of the Respironics recall, final court approval and implementation of the consent decree, and conditions for resuming US device sales.
- Final participation and payment levels under the economic-loss settlement, and developments in personal-injury claims, medical-monitoring claims and DOJ investigations.
- Whether declining order intake stabilizes and converts into revenue, and whether the order book continues to support growth.
- Whether 2024 improvement plans deliver stronger margins and cash flow, including the remaining workforce reductions and supply-chain actions.
- Liquidity, net debt and credit ratings, and any changes to the proposed share dividend.
- Sensitivity of Sleep & Respiratory Care goodwill to consent-decree assumptions: the filing reports EUR 326 million of headroom, which could be eliminated by specified adverse changes in key assumptions.